Business Description
Zymeworks Inc
NAICS : 325412
SIC : 2836
ISIN : US98985Y1082
Share Class Description:
ZYME: Registered ShsTotal Employee Number:
264Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 21.4 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.17 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.94 | |||||
Beneish M-Score | -3.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -39.4 | |||||
3-Year Book Growth Rate | -23 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.33 | |||||
9-Day RSI | 66.36 | |||||
14-Day RSI | 62.15 | |||||
3-1 Month Momentum % | -10.41 | |||||
6-1 Month Momentum % | 3.59 | |||||
12-1 Month Momentum % | 84.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.82 | |||||
Quick Ratio | 10.82 | |||||
Cash Ratio | 10.23 | |||||
Days Sales Outstanding | 59.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6 | |||||
Shareholder Yield % | -8.81 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -140.23 | |||||
Net Margin % | -126.33 | |||||
EBITDA Margin % | -123.6 | |||||
FCF Margin % | -95.43 | |||||
OCF Margin % | -92.68 | |||||
ROE % | -36.36 | |||||
ROA % | -24.97 | |||||
ROIC % | -93.42 | |||||
3-Year ROIIC % | 1716.61 | |||||
ROC (Joel Greenblatt) % | -347.86 | |||||
ROCE % | -30.32 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 23.88 | |||||
PS Ratio | 25.17 | |||||
PB Ratio | 12 | |||||
Price-to-Tangible-Book | 13.06 | |||||
EV-to-EBIT | -14.52 | |||||
EV-to-EBITDA | -16.06 | |||||
EV-to-Revenue | 19.85 | |||||
EV-to-Forward-Revenue | 5.21 | |||||
EV-to-FCF | -20.8 | |||||
Price-to-GF-Value | 1.07 | |||||
| Price-to-Net-Current-Asset-Value | 27.76 | |||||
| Price-to-Net-Cash | 39.19 | |||||
Earnings Yield (Greenblatt) % | -6.89 | |||||
FCF Yield % | -3.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZYME
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zymeworks Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 81.263 | ||
| EPS (TTM) ($) | -1.37 | ||
| Beta | 0.804 | ||
| 3-Year Sharpe Ratio | 0.96 | ||
| 3-Year Sortino Ratio | 1.85 | ||
| Volatility % | 48.51 | ||
| 14-Day RSI | 62.15 | ||
| 14-Day ATR ($) | 1.221731 | ||
| 20-Day SMA ($) | 24.21575 | ||
| 12-1 Month Momentum % | 84.79 | ||
| 52-Week Range ($) | 11.51 - 29.75 | ||
| Shares Outstanding (Mil) | 73.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zymeworks Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zymeworks Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-30 09:00 | In 175 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 29 days | ||
| TD Cowen 7th Annual Oncology Innovation Summit | 2026-05-27 16:30 | 25.40 (-0.78%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 27.61 (+2.37%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 27.61 (+2.37%) | ||
| Citizens Life Science Conference | 2026-03-11 10:10 | 25.46 (+1.92%) | ||
| Leerink Annual Global Healthcare Conference | 2026-03-09 15:00 | 24.08 (-4.03%) |
Show
Entries
Zymeworks Inc Frequently Asked Questions
What is Zymeworks Inc(ZYME)'s stock price today?
The current price of ZYME is $26.65. The 52 week high of ZYME is $29.75 and 52 week low is $11.51.
When is next earnings date of Zymeworks Inc(ZYME)?
The next earnings date of Zymeworks Inc(ZYME) is 2026-08-07 Est..
Does Zymeworks Inc(ZYME) pay dividends? If so, how much?
Zymeworks Inc(ZYME) does not pay dividend.
Guru Commentaries on NAS:ZYME
No articles.
Press Release
Articles on Zymeworks Inc
Headlines
See More- 1
Jun 29, 2026
Theravance downgraded at Jones on Zymeworks acquisition
Seeking Alpha • 1:36pm
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal
Seeking Alpha • 5:30am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers